Posaconazole therapeutic drug monitoring in pediatric patients and young adults with cancer;Seguimiento del FármacoTerapéutico Posaconazol en Pacientes Pediátricos y Adultos Jóvenes con Cáncer

Annals of Pharmacotherapy

Volumn 47, Issue 7-8, 2013, Pages 976-983

  Bernardo, Valeria A ^a,b   Cross, Shane J ^c,d   Crews, Kristine R ^c,d   Flynn, Patricia M ^e,f,g   Hoffman, James M ^c,d   Knapp, Katherine M ^c,g   Pauley, Jennifer L ^c,d   Molinelli, Alejandro R ^f   Greene, William L ^c,d  

^a Department of Pharmacy Practice   (United States)

^b SSM Cardinal Glennon Children's Medical Center   (United States)

^c St Jude Children's Research Hospital   (United States)

^d UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^e Translational Trials Unit   (United States)

^f ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^g UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; HISTAMINE H2 RECEPTOR ANTAGONIST; MICAFUNGIN; POSACONAZOLE; PROTON PUMP INHIBITOR; VORICONAZOLE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; ASPERGILLOSIS; BODY WEIGHT; CANCER PATIENT; CANDIDIASIS; CHILD; CLINICAL ARTICLE; CLINICAL STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG MONITORING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FUNGAL EYE INFECTION; HUMAN; INFANT; LIVER TOXICITY; LOW DRUG DOSE; LUNG ASPERGILLOSIS; MALE; NAUSEA; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRESCHOOL CHILD; PRIORITY JOURNAL; QT PROLONGATION; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; SCHOOL CHILD; SYSTEMIC MYCOSIS; VOMITING;

ADOLESCENT; ANTIFUNGAL AGENTS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; HUMANS; INFANT; MALE; NEOPLASMS; RETROSPECTIVE STUDIES; TRIAZOLES; YOUNG ADULT;

EID: 84880062692     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R775     Document Type: Article

References (23)

1. Product information. Noxafil (posaconazole) oral suspension. Kenilworth, NJ: Schering Corp., December 2012.
2. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007;44: 2-12.
3. Morris MI. Posaconazole: a new oral antifungal agent with an expanded spectrum of activity. Am J Health Syst Pharm 2009;66:225-36.
4. Greenberg RN, Mullane K, van Burik JAH, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006;50:126-33.
5. Krishna G, Moton A, Ma L, Medlock MM, McLeod JI. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother 2009; 53:958-66.
6. Dolton MJ, Ray JE, Chen SC, Ng K, Pont L, McLachlan AJ. Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration. Antimicrob Agents Chemother 2012;56:5503-10.
7. Howard SJ, Felton TW, Gomez-Lopez A, Hope WW. Posaconazole: the case for therapeutic drug monitoring. Ther Drug Monit 2012;34:72-6.
8. Hope WW, Billaud EM, Lestner J, Denning DW. Therapeutic drug monitoring for triazoles. Curr Opin Infect Dis 2008;21:580-6.
9. Hussaini T, Rüping MJ, Farowski F, Vehreschild JJ, Cornely OA. Therapeutic drug monitoring of voriconazole and posaconazole. Pharmacotherapy 2011;31:214-25.
10. Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 2009;53:24-34.
11. Dolton MJ, Ray JE, Marriott D, McLachlan AJ. Posaconazole exposureresponse relationship: evaluating the utility of therapeutic drug monitoring. Antimicrob Agents Chemother 2012;56:2806-13.
12. Ray J, Campbell L, Rudham S, Nguyen Q, Marriott D. Posaconazole plasma concentrations in critically ill patients. Ther Drug Monit 2011;33:387-92.
13. Common terminology criteria for adverse events v3.0 (CTCAE). http:// ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ ctcaev3.pdf (accessed 2011 Jun 24).
14. Heinz WJ, Zirkel J, Kuhn A, et al. Relevance of timing for determination of posaconazole plasma concentrations. Antimicrob Agents Chemother 2011;55:3621-3.
15. Krishna G, Sansone-Parsons A, Martinho M, Kantesaria B, Pedicone L. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob Agents Chemother 2007;51:812-8.
16. Lehrnbecher T, Attarbaschi A, Duerken M, et al. Posaconazole salvage treatment in paediatric patients: a multicentre survey. Eur J Clin Microbiol Infect Dis 2010;29:1043-5.
17. Zoller E, Valente C, Baker K, Klepser ME. Development, clinical utility, and place in therapy of posaconazole for prevention and treatment of invasive fungal infections. Drug Des Devel Ther 2010;4:299-311.
18. Jang S, Colangelo P, Gobburu J. Exposure-response of posaconazole for prophylaxis of invasive fungal infections: evaluation of the need for adjusting doses based on plasma drug concentrations. Clin Pharmacol Ther 2010;88:115-9.
19. Gubbins PO, Krishna G, Sansone-Parsons A, et al. Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients. Antimicrob Agents Chemother 2006;50:1993-9.
20. Ullmann AJ, Cornely OA, Burchardt A, et al. Pharmacokinetics, safety, and efficacy of posaconzole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006;50:658-66.
21. Kohl V, Müller C, Cornely OA, et al. Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. Antimicrob Agents Chemother 2010;54:207-12.
22. Thompson GR III, Rinaldi MG, Pennick G, Dorsey SA, Patterson TF, Lewis JS II. Posaconazole therapeutic drug monitoring: a reference laboratory experience. Antimicrob Agents Chemother 2009;53:2223-4.
23. Bryant AM, Slain D, Cumpston A, Craig M. A post-marketing evaluation of posaconazole plasma concentrations in neutropenic patients with haematological malignancy receiving posaconazole prophylaxis. Int J Antimicrob Agents 2011;37:266-9.